AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25147079 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2-0.4 mg daily)
Number of subjects: 291
Study 25147079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 23881862 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional programming with a ventricular tachycardia zone of 170 to 199 bpm (arm A)
Number of subjects: 1483
Study 23881862 — intervention group
Group type: EXPERIMENTAL
Intervention: High-rate cutoff with a ventricular tachycardia zone ≥200 bpm (arm B)
Number of subjects: 1483
Study 23881862 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-second-delayed therapy (arm C)
Number of subjects: 1483
Study 23881862 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 1483
Study 23881862 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate therapy in diabetic patients
Number of subjects: 1483
Study 23881862 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate therapy in diabetic patients
Number of subjects: 1483
Study 20827448 — intervention group
Group type: EXPERIMENTAL
Intervention: IR‐A irradiation treatment
Number of subjects: 207
Study 20827448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (visible, but not IR irradiation)
Number of subjects: 207
Study 20827448 — intervention group
Group type: COMPARATOR
Intervention: No irradiation
Number of subjects: 207
Study 18005966 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E supplementation (343 mg and 84 mg respectively)
Number of subjects: 34
Study 18005966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 18005966 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E supplementation
Number of subjects: 34
Study 16012275 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine dosage escalation to 400 mg/d in 5 days
Number of subjects: 69
Study 16012275 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine dosage escalation to 400 mg/d in 3 days
Number of subjects: 69
Study 16012275 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine dosage escalation to 400 mg/d in 2 days
Number of subjects: 69
Study 16012275 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 14616184 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Reasons for Smoking Scale (MRSS)
Number of subjects: 330
Study 14616184 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first cigarette after awakening
Number of subjects: 330
Study 14616184 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit/automatism score
Number of subjects: 330
Study 14616184 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of cigarettes smoked per day
Number of subjects: 330
Study 9892331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin (500 mg twice daily)
Number of subjects: 139
Study 9892331 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ciprofloxacin (200 mg twice daily)
Number of subjects: 139
Study 9892331 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin
Number of subjects: 139
Study 9892331 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ciprofloxacin
Number of subjects: 139
Study 8721128 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1
Number of subjects: 26
Study 8721128 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study 1816434 — intervention group
Group type: EXPERIMENTAL
Intervention: Isodinit
Number of subjects: 0
Study 1816434 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 0
Study 1816434 — intervention group
Group type: COMPARATOR
Intervention: Monizid
Number of subjects: 0
Study 6109047 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet containing leguminous fibre (HL) for 6 weeks
Number of subjects: 27
Study 6109047 — intervention group
Group type: COMPARATOR
Intervention: Standard low carbohydrate diet (LC) for 6 weeks
Number of subjects: 27
Study 30110179 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic intervention plus family coaching group (TU+)
Number of subjects: 360
Study 29433500 — intervention group
Group type: EXPERIMENTAL
Intervention: Local neck treatment
Number of subjects: 168
Study 29433500 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment plus tailored sensorimotor exercises
Number of subjects: 168
Study 29433500 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment plus balance exercises
Number of subjects: 168
Study 29433500 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment plus sensorimotor and balance exercises
Number of subjects: 168
Study 29433500 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 168
Study 29433500 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 168
Study 26708700 — intervention group
Group type: EXPERIMENTAL
Intervention: NNS beverages
Number of subjects: 303
Study 26708700 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 303
Study 24429539 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention consisting of print materials and 4 telephone-counseling calls delivered over 1 month
Number of subjects: 0
Study 24429539 — intervention group
Group type: COMPARATOR
Intervention: Print information-only control group
Number of subjects: 0
Study 22353925 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation (PS)
Number of subjects: 507
Study 22353925 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation (FS)
Number of subjects: 507
Study 22353925 — intervention group
Group type: EXPERIMENTAL
Intervention: PS + FS
Number of subjects: 507
Study 22353925 — intervention group
Group type: COMPARATOR
Intervention: Clinic-control
Number of subjects: 507
Study 22353925 — intervention group
Group type: COMPARATOR
Intervention: Hospital-control
Number of subjects: 507
Study 20647478 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (240 mg)
Number of subjects: 60
Study 20647478 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib (240 mg) plus ketoconazole
Number of subjects: 60
Study 20647478 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 60
Study 20647478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 20647478 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ketoconazole
Number of subjects: 60
Study 17582439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraspinal injections of autologous mesenchymal stem cells (MSCs) at the thoracic level
Number of subjects: 9
Study 17582439 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraspinal injections of autologous mesenchymal stem cells (MSCs)
Number of subjects: 9
Study 15729064 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective digestive decontamination (SDD)
Number of subjects: 117
Study 15729064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 11917904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (DHT; 70 mg/day) for 3 months
Number of subjects: 66
Study 11917904 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel for 3 months
Number of subjects: 66
Study 11917904 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related differences in muscle strength
Number of subjects: 66
Study 9623225 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7614103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 30 mg daily
Number of subjects: 203
Study 7614103 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg daily
Number of subjects: 203
Study 1978771 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin, 600 mg intravenously every 6 hours, followed by oral clindamycin, 300 mg every 6 hours for a minimum of 4 weeks.
Number of subjects: 37
Study 1978771 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G, 2 million U every 4 hours for no less than 8 days, followed by oral penicillin V, 750 mg every 6 hours for a minimum of 4 weeks.
Number of subjects: 37
Study 850696 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive stretch
Number of subjects: 30
Study 850696 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contraction
Number of subjects: 30
Study 850696 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 31116996 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) + photodynamic therapy (PDT)
Number of subjects: 36
Study 31116996 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 36
Study 28975543 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine injection (accelerated schedule)
Number of subjects: 202
Study 28975543 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B recombinant DNA vaccine (conventional schedule)
Number of subjects: 202
Study 25880756 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg QD
Number of subjects: 172
Study 25880756 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1600 mg QD
Number of subjects: 172
Study 25880756 — intervention group
Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 172
Study 23718748 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (n=32)
Number of subjects: 64
Study 23718748 — intervention group
Group type: COMPARATOR
Intervention: Insulin (n=32)
Number of subjects: 64
Study 21262871 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg/day for 6 months
Number of subjects: 27
Study 21262871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 18937965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irreversible P2Y12 receptor antagonists
Number of subjects: 0
Study 18937965 — intervention group
Group type: COMPARATOR
Intervention: Reversible P2Y12 receptor antagonists
Number of subjects: 0
Study 17932898 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release 17-beta estradiol-eluting R-Stent
Number of subjects: 95
Study 17932898 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-release 17-beta estradiol-eluting R-Stent
Number of subjects: 95
Study 17932898 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (control)
Number of subjects: 95
Study 15525860 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful Waiting Intervention (WWI) - 5 weekly intervention calls from a nurse
Number of subjects: 41
Study 15525860 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 41
Study 11575336 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg kg(‐1)
Number of subjects: 50
Study 11575336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9648974 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 1749
Study 8116135 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate
Number of subjects: 243
Study 8116135 — intervention group
Group type: COMPARATOR
Intervention: goserelin
Number of subjects: 243
Study 2752179 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (1 mg/kg/day)
Number of subjects: 32
Study 2752179 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous gamma-globulin (400 mg/kg on days 1 through 5)
Number of subjects: 32
Study 2752179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral prednisone and high-dose intravenous gamma-globulin
Number of subjects: 32
Study 2752179 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 165913 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl oestradiol 20 mug daily
Number of subjects: 17
Study 165913 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl oestradiol 50 mug daily
Number of subjects: 17
Study 165913 — intervention group
Group type: COMPARATOR
Intervention: conjugated equine oestrogens (Premarin) 0.625 mg daily
Number of subjects: 17
Study 165913 — intervention group
Group type: COMPARATOR
Intervention: conjugated equine oestrogens (Premarin) 1.25 mg daily
Number of subjects: 17
Study 30858635 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT + iv. ketamine
Number of subjects: 12
Study 30858635 — intervention group
Group type: COMPARATOR
Intervention: ECT + iv. placebo (midazolam)
Number of subjects: 12
Study 26537980 — intervention group
Group type: EXPERIMENTAL
Intervention: Managing Cancer Care: A Personal Guide (MCC) intervention
Number of subjects: 105
Study 26149210 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL articaine (4% with 1:100,000 epinephrine)
Number of subjects: 82
Study 26149210 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mL articaine (4% with 1:100,000 epinephrine)
Number of subjects: 82
Study 23176311 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed residual CPB volume
Number of subjects: 197
Study 23176311 — intervention group
Group type: COMPARATOR
Intervention: Unprocessed residual CPB volume (control)
Number of subjects: 197
Study 22453111 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A 100 U
Number of subjects: 60
Study 22453111 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin A 150 U
Number of subjects: 60
Study 22453111 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat onabotulinum toxin A injections (both doses)
Number of subjects: 60
Study 19207293 — intervention group
Group type: EXPERIMENTAL
Intervention: sTfR levels (3.50 +/- 0.07 mg/l)
Number of subjects: 560
Study 19207293 — intervention group
Group type: EXPERIMENTAL
Intervention: sTfR quartiles
Number of subjects: 560
Study 19207293 — intervention group
Group type: COMPARATOR
Intervention: Ferritin levels
Number of subjects: 560
Study 16225965 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 30
Study 16225965 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent condition
Number of subjects: 30
Study 16225965 — intervention group
Group type: COMPARATOR
Intervention: Younger adults
Number of subjects: 30
Study 16225965 — intervention group
Group type: COMPARATOR
Intervention: Non-famous names
Number of subjects: 30
Study 12051211 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate referral for lumbar spine x-ray
Number of subjects: 659
Study 12051211 — intervention group
Group type: COMPARATOR
Intervention: No referral for lumbar spine x-ray
Number of subjects: 659
Study 10730561 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha plus ketoprofen (group B)
Number of subjects: 49
Study 10730561 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha plus ribavirin (group C)
Number of subjects: 49
Study 10730561 — intervention group
Group type: COMPARATOR
Intervention: Interferon alpha alone (group A)
Number of subjects: 49
Study 7489418 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of plain bupivacaine with buprenorphine
Number of subjects: 30
Study 7489418 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 30
Study 1934866 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 1 mg/kg
Number of subjects: 8
Study 1934866 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 2 mg/kg
Number of subjects: 8
Study 1934866 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 4 mg/kg
Number of subjects: 8
Study 1934866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1934866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole
Number of subjects: 8
Study 6283800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre rich breakfast (whole grain bread and whole apples, 8.4 g dietary fibre)
Number of subjects: 8
Study 6283800 — intervention group
Group type: COMPARATOR
Intervention: Fibre poor breakfast (white bread and apple juice, 3.1 g dietary fibre)
Number of subjects: 8
Study 6360415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine plus diet
Number of subjects: 0
Study 6360415 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus diet
Number of subjects: 0
Study 30119663 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap fixation using ARTISS tissue glue with a low suction drain
Number of subjects: 336
Study 30119663 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap fixation using sutures and a low suction drain
Number of subjects: 336
Study 30119663 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound closure (without flap fixation) and low suction drainage
Number of subjects: 336
Study 27496149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 46
Study 27496149 — intervention group
Group type: COMPARATOR
Intervention: Control (waiting list)
Number of subjects: 46
Study 25225241 — intervention group
Group type: EXPERIMENTAL
Intervention: History of AFib
Number of subjects: 4120
Study 25225241 — intervention group
Group type: COMPARATOR
Intervention: No history of AFib
Number of subjects: 4120
Study 23134880 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional counseling and education about regular foods (group 1)
Number of subjects: 111
Study 23134880 — intervention group
Group type: COMPARATOR
Intervention: Dietary supplements and usual diet (group 2)
Number of subjects: 111
Study 23134880 — intervention group
Group type: COMPARATOR
Intervention: Usual diet without individualized counseling (group 3)
Number of subjects: 111
Study 20155838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antibiotics (doxycycline and rifampin)
Number of subjects: 42
Study 20155838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20155838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antibiotics
Number of subjects: 42
Study 17644537 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Erosion Narrowing Score (SENS)
Number of subjects: 0
Study 17644537 — intervention group
Group type: COMPARATOR
Intervention: Sharp-van der Heijde Score (SHS)
Number of subjects: 0
Study 15779531 — intervention group
Group type: EXPERIMENTAL
Intervention: Judged probability of a target cause when competing displayed causes have low support
Number of subjects: 0
Study 15779531 — intervention group
Group type: EXPERIMENTAL
Intervention: Judged probability of a target cause when competing displayed causes have high support
Number of subjects: 0
Study 15779531 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency estimation task for target causes
Number of subjects: 0
Study 12768894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 4% sodium chondroitin sulfate and 3% sodium hyaluronate
Number of subjects: 156
Study 12768894 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4% sodium hyaluronate
Number of subjects: 156
Study 12768894 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% hyaluronate
Number of subjects: 156
Study 12768894 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 156
Study 12768894 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 156
Study 10627795 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention
Number of subjects: 0
Study 10627795 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10172394 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural block with 1.2 mL/kg of 0.25% bupivacaine
Number of subjects: 24
Study 10172394 — intervention group
Group type: COMPARATOR
Intervention: Local infiltration with ilioinguinal/iliohypogastric block
Number of subjects: 24
Study 2025147 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity treatment (self-help booklet and 20-30 minute session with a trained counselor)
Number of subjects: 466
Study 2025147 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity treatment (low-level treatments plus individually tailored follow-up treatments)
Number of subjects: 466
Study 2025147 — intervention group
Group type: COMPARATOR
Intervention: Control (informational leaflet on smoking)
Number of subjects: 466
Study 7469210 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline, 100 mg once or twice daily for 7 or 21 days
Number of subjects: 289
Study 7469210 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 289
Study 30904540 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrastromal voriconazole (ISV) injection
Number of subjects: 70
Study 30904540 — intervention group
Group type: COMPARATOR
Intervention: Topical natamycin alone
Number of subjects: 70
Study 29150209 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV-IPV immunization schedules
Number of subjects: 1640
Study 25479118 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus usual care (8-minute video depicting cardiopulmonary resuscitation)
Number of subjects: 208
Study 25479118 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard pamphlet and routine discussions)
Number of subjects: 208
Study 25479118 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group
Number of subjects: 208
Study 25479118 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 208
Study 24147660 — intervention group
Group type: EXPERIMENTAL
Intervention: Double cerclage method
Number of subjects: 33
Study 24147660 — intervention group
Group type: COMPARATOR
Intervention: Classic McDonald cerclage method
Number of subjects: 33
Study 22226309 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathy treatment (individualized homeopathic medicines in fifty millesimal (LM) potencies)
Number of subjects: 81
Study 22226309 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (including analgesics, antipyretics, and anti-inflammatory drugs)
Number of subjects: 81
Study 19957840 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-door cervical expansive laminoplasty (ELP) with anchor fixation (group A)
Number of subjects: 44
Study 19957840 — intervention group
Group type: COMPARATOR
Intervention: Conventional silk thread fixation (group B)
Number of subjects: 44
Study 17570205 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT
Number of subjects: 18114
Study 17570205 — intervention group
Group type: EXPERIMENTAL
Intervention: FS
Number of subjects: 18114
Study 17570205 — intervention group
Group type: EXPERIMENTAL
Intervention: TC
Number of subjects: 18114